Prosecution Insights
Last updated: October 02, 2026

Cellartgen Inc.

Technology area: Biotechnology & Pharmaceuticals

7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Cellartgen Inc. maintains a portfolio within the Biotechnology & Pharmaceuticals technology area featuring 6 pending office actions. These matters are distributed across 5 distinct art units, suggesting that the company's research and development efforts span several specialized sub-sectors within the broader life sciences field. This distribution requires the applicant to navigate diverse examination standards across multiple administrative divisions at the patent office.

The prosecution workload involves 5 distinct examiners, which introduces a variety of individual perspectives into the portfolio's overall trajectory. THUESON, HANNA MARIE is identified as the busiest examiner for the company, currently handling 2 pending office actions. This concentration makes this specific examiner a significant point of contact for the company's legal representatives.

With 6 pending office actions and only 5 distinct examiners, the portfolio exhibits a high degree of examiner diversity relative to its size. The presence of 5 distinct art units further confirms that the legal strategy must account for varied technical requirements. Practitioners should monitor the 2 pending actions under THUESON, HANNA MARIE to identify potential trends or efficiencies in how the office evaluates the company's biotechnology claims.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

7
Total Pending OAs
2
Non-Final OAs
4
Final Rejections
1
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (43%)
3
Medium (43%)
1
Easy (14%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (29%)
§112 only1 (14%)
Double-patenting + other1 (14%)
Multi-statute (no §101)3 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
THUESON, HANNA MARIE 2 76.7% +28.2%
NICOL, ALEXANDER W 1 42.9% +43.1%
KIPOUROS, HOLLY MICHAELA 1 69.5% +21.6%
MELLER, MICHAEL V 1 47.1% +28.2%
SCHUBERG, LAURA J 1 23.6% +37.0%
BEHARRY, ZANNA MARIA 1 24.7% +56.4%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18355798 DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF THUESON, HANNA MARIE —
18347763 ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF THUESON, HANNA MARIE —
18324601 TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME SCHUBERG, LAURA J —
18253047 PANCREAS EXTRACELLULAR MATRIX DERIVED SCAFFOLD FOR CULTURE AND TRANSPLANTATION OF PANCREATIC ORGANOID AND METHOD OF PREPARING THE SAME BEHARRY, ZANNA MARIA —

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18539379 MULTI-ORGAN MODEL NICOL, ALEXANDER W —
18479843 MICROFLUIDIC HANGING DROP CULTURE DEVICE FOR CULTURING CELL AGGREGATE KIPOUROS, HOLLY MICHAELA —
18475303 PHENOL DERIVATIVE-MODIFIED, TISSUE-DERIVED EXTRACELLULAR MATRIX DERIVATIVE FOR CONSTRUCTION OF ARTIFICIAL TISSUE MELLER, MICHAEL V —
18355798 DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF THUESON, HANNA MARIE —
18347763 ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF THUESON, HANNA MARIE —
18324601 TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME SCHUBERG, LAURA J —
18253047 PANCREAS EXTRACELLULAR MATRIX DERIVED SCAFFOLD FOR CULTURE AND TRANSPLANTATION OF PANCREATIC ORGANOID AND METHOD OF PREPARING THE SAME BEHARRY, ZANNA MARIA —

Top Art Units

Art UnitApps
1638 2
1634 1
1799 1
1655 1
1631 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18539379 MULTI-ORGAN MODEL NICOL, ALEXANDER W 1634 §102§103DP Non-Final OA — Pending Dec 14, 2023
18479843 MICROFLUIDIC HANGING DROP CULTURE DEVICE FOR CULTURING CELL AGGREGATE KIPOUROS, HOLLY MICHAELA 1799 §103 Final Rejection — Pending Oct 03, 2023
18475303 PHENOL DERIVATIVE-MODIFIED, TISSUE-DERIVED EXTRACELLULAR MATRIX DERIVATIVE FOR CONSTRUCTION OF ARTIFICIAL TISSUE MELLER, MICHAEL V 1655 §112 Final Rejection — Pending Sep 27, 2023
18355798 DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF THUESON, HANNA MARIE 1638 §103§112 Final Rejection — Pending Jul 20, 2023
18347763 ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF THUESON, HANNA MARIE 1638 §102§103 Final Rejection — Pending Jul 06, 2023
18324601 TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME SCHUBERG, LAURA J 1631 §103 Non-Final OA — Pending May 26, 2023
18253047 PANCREAS EXTRACELLULAR MATRIX DERIVED SCAFFOLD FOR CULTURE AND TRANSPLANTATION OF PANCREATIC ORGANOID AND METHOD OF PREPARING THE SAME BEHARRY, ZANNA MARIA 1632 §102§112 Non-Final OA — Pending May 16, 2023

Managing Cellartgen Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month